<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796259</url>
  </required_header>
  <id_info>
    <org_study_id>20.21.NRC</org_study_id>
    <nct_id>NCT04796259</nct_id>
  </id_info>
  <brief_title>Malt-derived Ingredients and Their Prolactinotrophic Effects</brief_title>
  <official_title>Malt-derived Ingredients and Their Prolactinotrophic Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proof-of-concept study aims to investigate whether malt-derived ingredients have acute&#xD;
      prolactinotrophic effects in healthy women of child-bearing age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">April 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prolactinotrophic effect</measure>
    <time_frame>2 hours post consumption</time_frame>
    <description>Δ of serum Prolactin Cmax between test products, positive control of beer solids and negative control of still water</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal tolerability</measure>
    <time_frame>2 hours post consumption</time_frame>
    <description>• Gastro-intestinal tolerability assessment with a visual analogue scale for each symptom of interest i.e.1) Abdominal discomfort 2) Nausea 3) Vomiting 4) Diarrhoea 5) ↓appetite.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acute Response to Food Ingredient Consumption</condition>
  <arm_group>
    <arm_group_label>Negative control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-alcoholic beer solids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Malt ingredient I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Malt ingredient II</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Malt ingredient</intervention_name>
    <description>Solution with malt-derived ingredient</description>
    <arm_group_label>Intervention 1</arm_group_label>
    <arm_group_label>Intervention 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Non-alcoholic beer solids</intervention_name>
    <description>Solution with non-alcoholic beer solids</description>
    <arm_group_label>Positive control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who have/are&#xD;
&#xD;
               1. Willing and able to provide written informed consent&#xD;
&#xD;
               2. Healthy women aged 18 to 40.&#xD;
&#xD;
               3. BMI in the range of 18 to 30.&#xD;
&#xD;
               4. Willing to undergo an experiment in the follicular phase of the menstrual cycle&#xD;
                  i.e. day 0 to 14 of the menstrual cycle starting from the first day of the&#xD;
                  period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have/are&#xD;
&#xD;
          -  Allergic to tested products&#xD;
&#xD;
          -  Under regular medication including oral contraceptive pills or other form of hormonal&#xD;
             replacement therapy.&#xD;
&#xD;
          -  Under medications which affects prolactin levels.&#xD;
&#xD;
          -  Pregnant or lactating or planning to conceive during the study period.&#xD;
&#xD;
          -  Smokers, or excessive alcohol consumption (alcohol intake higher than 2 servings per&#xD;
             day. A serving is 0.4 dl of strong alcohols, 1 dl of red or white wine, or 3 dl of&#xD;
             beer) or other substance abuse.&#xD;
&#xD;
          -  Not willing and/or not able to comply with the study procedures and requirements.&#xD;
&#xD;
          -  Suffering from pre-existing medical conditions and chronic illnesses that in the&#xD;
             opinion of the investigator may interfere with the study.&#xD;
&#xD;
          -  Family or hierarchical relationships with research team members&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose M. Ramos Nieves, M.Sc.; Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Société des Produits Nestlé S.A./NIHS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pamela Sun</last_name>
    <role>Study Director</role>
    <affiliation>Société des Produits Nestlé S.A./CIL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Société des produits Nestlé/Metabolic Unit</name>
      <address>
        <city>Lausanne</city>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

